Published in Arch Intern Med on March 14, 2005
Women's Health Initiative (WHI) | NCT00000611
My Lifestyle Intervention of Food and Exercise (MyLIFE) | NCT01630499
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) (2009) 1.41
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2008) 1.36
Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat (2011) 1.29
Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int (2008) 1.25
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol (2008) 1.12
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res (2012) 1.03
The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol (2012) 1.00
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab (2009) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer (2010) 0.94
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat (2011) 0.94
Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial. Osteoporos Int (2011) 0.93
Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil (2011) 0.93
Low Bone Mineral Density in Middle-Aged Breast Cancer Survivors: Prevalence and Associated Factors. Breast Care (Basel) (2012) 0.93
Aromatase inhibitors and bone loss. Oncology (Williston Park) (2006) 0.92
Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer (2011) 0.91
Health-related quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. J Cancer Surviv (2011) 0.90
Weight Lifting and Physical Function Among Survivors of Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. J Clin Oncol (2015) 0.89
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res (2011) 0.88
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.87
The influence of therapeutic radiation on the patterns of bone marrow in ovary-intact and ovariectomized mice. PLoS One (2012) 0.86
Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr (2009) 0.84
The management of osteoporosis in breast cancer survivors. Maturitas (2012) 0.84
A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone (2014) 0.83
Skeletal Blood Flow in Bone Repair and Maintenance. Bone Res (2013) 0.83
Long-term Toxicity of Cancer Treatment in Older Patients. Clin Geriatr Med (2015) 0.83
Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients. J Bone Miner Metab (2009) 0.83
Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study. J Bone Miner Metab (2008) 0.82
The influence of therapeutic radiation on the patterns of bone remodeling in ovary-intact and ovariectomized mice. Calcif Tissue Int (2013) 0.82
Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc (2013) 0.81
Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat (2007) 0.80
Antagonizing the αv β3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading. J Bone Miner Res (2014) 0.80
Vitamin d deficiency in postmenopausal breast cancer survivors. J Womens Health (Larchmt) (2012) 0.80
Fracture in asian women with breast cancer occurs at younger age. PLoS One (2013) 0.80
Spatial and temporal fracture pattern in breast and gynecologic cancer survivors. J Cancer (2015) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Comparison of tai chi vs. strength training for fall prevention among female cancer survivors: study protocol for the GET FIT trial. BMC Cancer (2012) 0.79
Cancer Survivorship Care: Summarizing the 6 Tools for Success. Fed Pract (2011) 0.79
Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study. Support Care Cancer (2013) 0.79
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone (2008) 0.78
Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. J Cancer Sci Ther (2011) 0.78
Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep (2012) 0.78
The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther (2009) 0.77
A Preliminary Study on the Efficacy of a Community-Based Physical Activity Intervention on Physical Function-Related Risk Factors for Falls Among Breast Cancer Survivors. Am J Phys Med Rehabil (2016) 0.77
Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep (2013) 0.77
Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study. BMC Musculoskelet Disord (2015) 0.77
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol (2012) 0.77
Advancing breast cancer survivorship among African-American women. Breast Cancer Res Treat (2015) 0.76
Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study. PLoS One (2015) 0.76
Soy isoflavone intake and bone mineral density in breast cancer survivors. Cancer Causes Control (2015) 0.75
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls. J Bone Rep Recomm (2016) 0.75
Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res (2012) 0.75
The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med (2009) 0.75
Detailed methods of two home-based vegetable gardening intervention trials to improve diet, physical activity, and quality of life in two different populations of cancer survivors. Contemp Clin Trials (2016) 0.75
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporos Int (2014) 0.75
Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada. Osteoporos Int (2017) 0.75
Design of a randomised intervention study: the effect of dumbbell exercise therapy on physical activity and quality of life among breast cancer survivors in Malaysia. BMJ Glob Health (2016) 0.75
Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis. Osteoporos Int (2014) 0.75
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med (2009) 12.38
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol (2009) 3.91
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials (2002) 3.41
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med (2008) 3.12
Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell (2008) 3.08
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol (2003) 3.03
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Researching complementary and alternative treatments--the gatekeepers are not at home. BMC Med Res Methodol (2007) 2.96
The status of public reporting of clinical outcomes in assisted reproductive technology. Fertil Steril (2013) 2.93
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst (2003) 2.64
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 2.50
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Symptom experience after discontinuing use of estrogen plus progestin. JAMA (2005) 2.32
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab (2012) 2.25
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr (2011) 2.21
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med (2005) 2.17
American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol (2009) 2.12
Low-intensity IVF: real progress? Reprod Biomed Online (2011) 2.08
Gender differences in academic advancement: patterns, causes, and potential solutions in one US College of Medicine. Acad Med (2003) 2.07
Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol (2011) 2.02
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01
Complementary and alternative medicine whole systems research: beyond identification of inadequacies of the RCT. Complement Ther Med (2005) 1.97
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Association of nonmelanoma skin cancer with second malignancy. Cancer (2004) 1.82
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med (2003) 1.81
Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am J Epidemiol (2007) 1.80
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum (2008) 1.80
Increases in plasma carotenoid concentrations in response to a major dietary change in the women's healthy eating and living study. Cancer Epidemiol Biomarkers Prev (2006) 1.78
Effects of questionnaire-based diagnosis and training on inter-rater reliability among practitioners of traditional Chinese medicine. J Altern Complement Med (2009) 1.77
Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med (2007) 1.75
Telephone counseling intervention increases intakes of micronutrient- and phytochemical-rich vegetables, fruit and fiber in breast cancer survivors. J Nutr (2004) 1.75
Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol (2009) 1.75
Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 1.73
Statistical issues arising in the Women's Health Initiative. Biometrics (2005) 1.72
Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit. Fertil Steril (2005) 1.72
Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril (2008) 1.72
Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr (2010) 1.67
Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the Women's Health Initiative Observational Study. Arthritis Care Res (Hoboken) (2011) 1.64
Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reprod Biomed Online (2010) 1.64
The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol (2012) 1.62
The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbance in women with breast cancer: an exploratory study. J Psychosom Res (2003) 1.60
Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol (2009) 1.60
Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One (2011) 1.60
Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause (2011) 1.59
Gender as risk factor for autoimmune diseases. J Autoimmun (2007) 1.58
Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol (2006) 1.55
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 1.54
Randomized trial of two mind-body interventions for weight-loss maintenance. J Altern Complement Med (2007) 1.51
Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50
Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril (2010) 1.49
Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause (2010) 1.47
Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol (2011) 1.47
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res (2006) 1.45
Traditional versus telenursing outpatient management of patients with cancer with new ostomies. Oncol Nurs Forum (2004) 1.45
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Hype or hope? Ethical and practical considerations with clinical research in women with diminished ovarian reserve. Reprod Biomed Online (2012) 1.41
Advanced reproductive age and maternal mortality. Obstet Gynecol (2015) 1.40
Preimplantation genetic screening (PGS) still in search of a clinical application: a systematic review. Reprod Biol Endocrinol (2014) 1.39
Successful treatment of unresponsive thin endometrium. Fertil Steril (2011) 1.38
Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online (2010) 1.38
Review of treatment modalities for postmenopausal osteoporosis. South Med J (2005) 1.37
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause (2012) 1.35
Recruitment of Hispanic women to the Women's Health Initiative. the case of Embajadoras in Arizona. Control Clin Trials (2002) 1.35
Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med (2008) 1.34
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol (2008) 1.34